Loading company…
LYMPHOGENiX develops therapies and research products related to lymphatic health.
Founded in 2024 and based in London, UK, LYMPHOGENiX develops therapies to improve lymphatic function in humans and animals. Its Vessely candidate targets endometrial lymphatic health, and the company also offers collaborative research and development and reagents. In July 2025, it raised GBP 260,000 in pre-seed funding from GLOCALINK and Keio Innovation Initiative.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in